SciSparc's 15min chart shows Bollinger Bands expanding downward, bearish marubozu formation.

SciSparc's 15-minute chart has recently exhibited a pattern of expanding downward Bollinger Bands and a bearish Marubozu at 10/03/2025 11:00, which suggests that the market trend is currently being driven by a strong selling influence. As a result, it is likely that the bearish momentum will continue in the near term.

SciSparc Ltd. (NASDAQ: SPRC) stock surged by 33% on Tuesday following the approval of the acquisition of its majority-owned subsidiary, MitoCareX Bio Ltd., by N2OFF Inc. (NASDAQ: NITO). The approval, which came during a special meeting held on September 25, 2025, represents a significant milestone in the acquisition process. Under the terms of the agreement announced on February 25, 2025, N2OFF will purchase 6,622 shares of MitoCareX for $700,000 and exchange the remaining shares with SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri for N2OFF common stock, totaling 40% of N2OFF’s fully diluted capital stock SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1].

The sellers will receive 30% of N2OFF’s financing proceeds (capped at $1.6 million) over five years following the closing of the transaction. Additionally, they may receive milestone-based issuances of up to 25% of N2OFF common stock on a fully diluted basis. N2OFF has committed to financially supporting MitoCareX’s operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending the satisfaction of remaining conditions SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1].

MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031, according to Coherent Market Insights SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1].

This acquisition is expected to strengthen SciSparc's portfolio and position it for further growth in the biopharmaceutical sector. The surge in SciSparc's stock price reflects investor confidence in the potential of this strategic move.